Fropper.com Blogs – Free Blogging

relationship

<< Thyroid Profile (TPC 3rd Generation) | Main | Anti Nuclear Antibodies (ANA) >>

Posted on: Aug 25, '08

CA 19.9

CA 19.9
Elevated CA 19.9 values are frequently found in the serum of persons with gastrointestinal malignancies such as
Pancreatic, Colorectal, Gastric and Hepatic Carcinomas.

A persistently rising CA 19.9 value may be associated with progressive malignant disease and poor therapeutic
response. Benign conditions such as Pancreatitis and Hepatitis can cause elevated serum concentrations, but most of
these are below 120 U/ml.

Although useful as an adjunct in cancer diagnosis, it should not be considered as screening or diagnostic test when
used alone.

Comments:

IMMULITE CLIA BASED CA 19.9 Assay (DPC LABORATORIES)

Expected Values:

96.60% of Healthy Individuals: Below 37.00 U/mL.

CA 19.9 is a useful Tumour Marker especially for already diagnosed PANCREATIC ADENOCARCINOMAS and abdominal
malignancies. Baseline levels measured prior to therapeutic intervention, and followed later by serial periodical
measurements, will enable the treating doctor to predict outcome of the therapy. They also help in early discovery of
recurrences, relapses and metastases.

In general, Tumour Marker level which is more important, rather than it’s absolute value. A 50% change can be
considered clinically significant. As with other Tumour Markers, CA 19.9 should not be used along, but in
conjunction with other clinical criteria. Combined use of CA 19.9 and CEA increases sensitivity, specificity and
predictability of Tumour Markers in PANCREATIC ADENOCARCINOMA. It must be emphasised that CA 19.9 may also be
elevated in HEPATOMA, cancers of the STOMACH, BILARY DUCT, COLON, LUNGS, BREAST and dome non-malignant conditions
speciality LIVER NECROSIS. Therefore, it should never be used as a screening test for diagnosing Pancreatic
Adenocarcinoma, but only as an aid in follow-up

studies.

Methodology of Test: Chemiluminescence.

Tags: news, ayan

12 Comment(s) |